Compare · CYAN vs GRPH
CYAN vs GRPH
Side-by-side comparison of Cyanotech Corporation (CYAN) and Graphite Bio Inc. (GRPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYAN and GRPH operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- GRPH has more recent analyst coverage (16 ratings vs 0 for CYAN).
- Company
- Cyanotech Corporation
- Graphite Bio Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 16
Cyanotech Corporation
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Graphite Bio Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Latest CYAN
- SEC Form 15-12G filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- SEC Form SC 13E3 filed by Cyanotech Corporation
- SEC Form 10-Q filed by Cyanotech Corporation
- Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026
- SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.
- SEC Form 3 filed by new insider Miyashiro Jennifer A.S.
- Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)
- Director Vied David L was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 29% to 225,138 units (SEC Form 4)
Latest GRPH
- Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form 10-Q filed by Graphite Bio Inc.
- Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form EFFECT filed by Graphite Bio Inc.
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)
- Graphite Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form S-1 filed by Graphite Bio Inc.
- New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)